Press Release, May 4, 2009
Diamyd Medical reports that the respected scientific journal Diabetologia has
published an article containing the results of a study demonstrating that the
Diamyd® vaccine significantly reduces the risk that patients with LADA (Latent
Autoimmune Diabetes in Adults) will require treatment with insulin still after
five years. The results that now have been published, were previously presented
at the EASD meeting in Rome, August 2008.
Approximately ten percent of all diabetes patients have LADA, and patients with
the disease normally require treatment with insulin within a few years from
diagnosis.
”Increasing attention is being paid to LADA patients as a group. There is
currently no treatment that can slow the course of the disease, and our positive
results are receiving a lot of attention from both doctors and patients," says
Elisabeth Lindner, President and CEO of Diamyd Medical.
The title of the article is “GAD65 vaccination: 5 years of follow-up in a
randomised dose-escalating study in adult-onset autoimmune diabetes.” The
authors are C.-D. Agardh, K. F. Lynch, M. Palmér, K. Link and Å. Lernmark.
The study included 47 LADA patients who were, with a four week interval, treated
with two injections of the Diamyd® diabetes vaccine in varying doses or with
placebo. The patients were then followed for five years. The patients treated
with 20 micrograms of Diamyd® showed the best results. The results after five
years demonstrate that the Diamyd® vaccine significantly reduced the risk that
the patient would need insulin treatment compared with placebo. The vaccine has
also proven to be safe, and has not been linked with any serious side effects.
The article is published on the journal's website
(www.diabetologia-journal.org), and will also be published in the print edition
in the near future. The article is available for free for one month via the
following link:
http://www.springerlink.com/content/f612483413663654/fulltext.pdf.
Diabetologia is the leading European scientific journal in the diabetes field.
Diabetologia is a monthly publication; the print edition has a circulation of
7,000.
For additional information, please contact:
Elisabeth Lindner, President and CEO Diamyd Medical AB (publ.)
Tel: +46 (0)8 6610026
For pictures and press material, please contact:
Alexandra Fleetwood, Director Communications Diamyd Medical AB (publ.),
alexandra.fleetwood@diamyd.com
Tel: +46 (0)8 661 0026
About Diamyd Medical
Diamyd Medical is a Swedish biopharmaceutical company focusing on the
development of pharmaceuticals for the treatment of autoimmune diabetes and its
complications. The company's most advanced project is the GAD-based drug Diamyd®
for type 1 diabetes. Phase III trials for this drug are in progress in both the
US and Europe. In addition, the Company has started clinical studies in the US
in the area of chronic pain, using its Nerve Targeting Drug Delivery System. The
Company has also out-licensed the use of GAD for the treatment of Parkinson's
disease.
Diamyd Medical has offices in Sweden and in the US. Shares are listed on the
Nasdaq OMX Nordic (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY)
administered by the Pink OTC Markets and the Bank of New York (PAL). Further
information is available on the company's website: www.diamyd.com.
This information is disclosed in accordance with the Swedish Securities Markets
Act, the Swedish Financial Instruments Trading Act, or the requirements stated
in the listing agreements.
Diamyd Medical AB (publ.)
Linnégatan 89 B, SE-115 23 Stockholm, Sweden. Tel: +46 (0)8 6610026, Fax: +46
(0)8 661 63 68
E-mail: info@diamyd.com. VAT no: SE556530-142001.
(www.omxnordicexchange.com ticker: DIAM B; www.otcqx.com ticker: DMYDY)
